Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center in the Philadelphia Navy Yard

09/28/2021 | 05:00pm EST

Iovance Biotherapeutics, Inc. is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, manufacturing facility dedicated to producing TIL cell therapies for patients with solid tumor cancers. The current capacity is expected to meet potential demand for thousands of patients per year with multiple types of cancers, including clinical trial patients and future commercial patients. Located at 300 Rouse Boulevard and with approximately 136,000 square feet of space, the iCTC is among the large cell therapy manufacturing facilities today. The iCTC is currently supplying Iovance clinical studies, and commercial manufacturing is expected to begin after initial product approval. The iCTC was developed and built by Gattuso Development Partners, LLC and the design and construction management firm CRB. Financial incentives were provided by the Commonwealth of Pennsylvania, the City of Philadelphia, and PIDC, including the site’s designation as a Keystone Opportunity Improvement Zone, which allows incentives for business development.


© S&P Capital IQ 2021
All news about IOVANCE BIOTHERAPEUTICS, INC.
11/22Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
11/19Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
11/15Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cance..
AQ
11/15Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pemb..
AQ
11/13IOVANCE BIOTHERAPEUTICS : SITC 2021 Update Call Presentation
PU
11/13Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pemb..
AQ
11/13Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pemb..
CI
11/12Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cance..
AQ
11/12Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cance..
CI
11/09Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL)..
GL
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -330 M - -
Net cash 2021 502 M - -
P/E ratio 2021 -8,45x
Yield 2021 -
Capitalization 2 862 M 2 862 M -
EV / Sales 2021 -
EV / Sales 2022 740x
Nbr of Employees 241
Free-Float 91,0%
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 18,24 $
Average target price 39,85 $
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Frederick G. Vogt President, CEO, Secretary & General Counsel
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Igor P. Bilinsky Chief Operating Officer
Sector and Competitors